How patients and doctors value different outcomes after coronary stent procedures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational questionnaire study invites adults with acute or chronic coronary syndrome who have undergone PCI and healthcare providers who treat coronary artery disease to rate the relative importance of individual events that commonly make up composite endpoints. Participants complete structured preference questionnaires asking them to weight or rank outcomes such as death, myocardial infarction, repeat revascularization, and bleeding. The study then compares patient and provider weights to identify differences in perceived importance across components. Findings are intended to inform whether weighted composite endpoints should better reflect patient priorities in future clinical trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with acute or chronic coronary syndrome who have undergone percutaneous coronary intervention;
2. Patients who can understand the purpose of this trial and are willing to participate in the preference questionnaire.
3. Healthcare providers who treat patients with coronary artery disease.

Exclusion Criteria:

1. Aged \< 18 years;
2. Inability to understand the questionnaire or presence of cognitive impairment.

Where it's running

• Xijing Hospital
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Ruining Zhang, BSc
• Email: ruining-zhang@qq.com
• Phone: 86-15802990370

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• What affects bleeding control and how long you need to lie flat after femoral arterial sheath removal

  We will see if patient and procedure factors can predict how long ICU patients need compression and bed rest after femoral arterial sheath removal to prevent bleeding and hematoma.

  Recruiting National Taiwan University Hospital · Taipei · NCT07469397

• Doctors' and patients' preferences for PCI implantation devices

  This questionnaire tests what patients who have had PCI and the doctors who treat them prefer between drug-eluting stents and drug-coated balloons.

  Recruiting Xijing Hospital · Xi'an, Shannxi · NCT07378163

• Flozins to prevent contrast-related kidney injury after coronary angiography or PCI

  This project tests whether taking a flozin (empagliflozin or dapagliflozin), short-term or long-term, lowers the chance of contrast-induced acute kidney injury in patients having coronary angiography or PCI.

  Recruiting Collegium Medicum w Bydgoszczy · Bydgoszcz · NCT07231939

• Temporary heart support with the iVAC 2L device during high-risk coronary procedures

  This trial will try the iVAC 2L temporary heart‑support device during high‑risk PCI to help people with severe coronary artery disease stay hemodynamically stable through the procedure.

  Recruiting National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Moscow · NCT07149714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.